# Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches

> **NCT02270957** · PHASE2 · COMPLETED · sponsor: **Oklahoma Medical Research Foundation** · enrollment: 66 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Abatacept
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02270957
- **Lead sponsor:** Oklahoma Medical Research Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2018-12
- **Final completion:** 2021-12
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2022-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02270957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02270957, "Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02270957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*